Tower Research Capital (TRC)’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,636
| Closed | -$90K | – | 6975 |
|
|
2022
Q2 | $90K | Sell |
1,636
-535
| -25% | -$28.1K | ﹤0.01% | 2382 |
|
|
2022
Q1 | $70K | Buy |
2,171
+866
| +66% | +$24.8K | ﹤0.01% | 2471 |
|
|
2021
Q4 | $28K | Buy |
+1,305
| New | +$28.8K | ﹤0.01% | 3327 |
|
|
2021
Q2 | – | Sell |
-388
| Closed | -$7K | – | 6157 |
|
|
2021
Q1 | $7K | Sell |
388
-1,514
| -80% | -$24K | ﹤0.01% | 4573 |
|
|
2020
Q4 | $30K | Buy |
1,902
+1,521
| +399% | +$21.1K | ﹤0.01% | 3582 |
|
|
2020
Q3 | $4K | Sell |
381
-5,753
| -94% | -$68.5K | ﹤0.01% | 4465 |
|
|
2020
Q2 | $74K | Buy |
6,134
+5,816
| +1,829% | +$72.2K | ﹤0.01% | 2735 |
|
|
2020
Q1 | $3K | Buy |
+318
| New | +$4.17K | ﹤0.01% | 2519 |
|
|
2019
Q2 | – | Sell |
-146
| Closed | -$10K | – | 4545 |
|
|
2019
Q1 | $10K | Buy |
+146
| New | +$9.37K | ﹤0.01% | 2701 |
|
|
2018
Q4 | – | Sell |
-129
| Closed | -$9K | – | 4556 |
|
|
2018
Q3 | $9K | Sell |
129
-99
| -43% | -$8.98K | ﹤0.01% | 2855 |
|
|
2018
Q2 | $27K | Buy |
228
+131
| +135% | +$13.1K | ﹤0.01% | 2250 |
|
|
2018
Q1 | $8K | Buy |
97
+63
| +185% | +$7.14K | ﹤0.01% | 2570 |
|
|
2017
Q4 | $5K | Buy |
+34
| New | +$3.27K | ﹤0.01% | 2934 |
|
|
2017
Q2 | – | Sell |
-40
| Closed | -$2K | – | 3687 |
|
|
2017
Q1 | $2K | Buy |
+40
| New | +$2.33K | ﹤0.01% | 2701 |
|
|
2016
Q4 | – | Sell |
-350
| Closed | -$26K | – | 4589 |
|
|
2016
Q3 | $26K | Buy |
350
+306
| +695% | +$23.6K | ﹤0.01% | 1471 |
|
|
2016
Q2 | $4K | Buy |
44
+29
| +193% | +$5.53K | ﹤0.01% | 3583 |
|
|
2016
Q1 | $4K | Buy |
15
+10
| +200% | +$3.19K | ﹤0.01% | 2962 |
|
|
2015
Q4 | $3K | Sell |
5
-50
| -91% | -$33.8K | ﹤0.01% | 3563 |
|
|
2015
Q3 | $45K | Buy |
+55
| New | +$62K | ﹤0.01% | 1102 |
|
Other funds holding SRRA
Tower Research Capital (TRC)'s SRRA Position: Q3 2022 in Review
Tower Research Capital (TRC) sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 1,636 shares — an estimated $90K sold.
Tower Research Capital (TRC) first reported a position in SRRA in Q3 2015 and held it in 19 quarters. The position peaked at $90K in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- Tower Research Capital (TRC) reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,636 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $90K.
- Tower Research Capital (TRC) first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 19 quarters.
- Tower Research Capital (TRC)'s Sierra Oncology, Inc. Common Stock position peaked at $90K in Q2 2022.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.